Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Antibodies targeting TIGIT, IL-27, CCR8 and BTLA from the Chinese and US firms are among the first batch of combination candidates expected to expand the indications of anti-PD-1 antibody Loqtorzi beyond the rare condition of nasopharyngeal carcinoma.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
Plus deals involving Sanofi/Adocia, Sirnaomics/EDIRNA, Eisai/DRI Healthcare, Sangamo/Voyager, Liquidia/Pharmosa, Tonix/Upsher-Smith and more.
Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.
- Contract Research Organization-CRO
- Research, Analytical Equipment & Supplies
- Drug Discovery Technologies
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Eucure Biopharma
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.